$250 | Single User
$500 | Site License
$750 | Global License

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

Published by Global Data: 09 Nov 2018 | 226958 | In Stock

Introduction

Summary

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
for Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 6

    List of Figures 6

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

    Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

    Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

    Venture Financing 13

    Karyopharm Therapeutics Raises US.2 Million In Series B Venture Financing 13

    Partnerships 15

    Veristat Enters into Agreement with Karyopharm Therapeutics 15

    Licensing Agreements 16

    Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16

    ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17

    Equity Offering 18

    Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18

    Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20

    Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22

    Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23

    Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24

    Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26

    Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28

    Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30

    Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US5 Million 32

    Debt Offering 34

    Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34

    Asset Transactions 35

    Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35

    Karyopharm Therapeutics Inc - Key Competitors 36

    Karyopharm Therapeutics Inc - Key Employees 37

    Karyopharm Therapeutics Inc - Locations And Subsidiaries 38

    Head Office 38

    Other Locations & Subsidiaries 38

    Recent Developments 39

    Financial Announcements 39

    Aug 07, 2018: Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress 39

    May 10, 2018: Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress 42

    Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress 45

    Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 48

    Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 51

    May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 52

    Corporate Communications 55

    Oct 26, 2018: Karyopharm Therapeutics announces management change 55

    Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 56

    Apr 03, 2017: Karyopharm Announces Management Change 58

    Product News 59

    12/10/2017: Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting 59

    12/10/2017: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting 61

    09/20/2017: Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma 64

    06/25/2018: Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 66

    06/15/2018: Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting 68

    06/01/2018: Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 71

    Product Approvals 74

    Jul 18, 2018: Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma 74

    Apr 10, 2018: Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma 76

    Clinical Trials 77

    May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 77

    May 16, 2018: Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 79

    Apr 30, 2018: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma 81

    Mar 19, 2018: Karyopharm to Present Preclinical Data On Eltanexor at the American Association for Cancer Research 2018 Annual Meeting 83

    Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting 84

    Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting 85

    Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 87

    Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 88

    Nov 01, 2017: Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting 89

    Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 92

    Sep 08, 2017: Karyopharm Announces Presentation of Selinexor Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 93

    Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 94

    Aug 30, 2017: Karyopharm Announces the Presentation of Selinexor Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 95

    Aug 08, 2017: Karyopharm Provides Update on Selinexor (KPT-330) 96

    Jun 23, 2017: Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting 98

    Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma 100

    May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting 101

    Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting 102

    Appendix 104

    Methodology 104

    About GlobalData 104

    Contact Us 104

    Disclaimer 104

List Of Tables
in Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

List of Tables

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karyopharm Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Karyopharm Therapeutics Raises US.2 Million In Series B Venture Financing 13

Veristat Enters into Agreement with Karyopharm Therapeutics 15

Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17

Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18

Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20

Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22

Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23

Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24

Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26

Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28

Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30

Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US5 Million 32

Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34

Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35

Karyopharm Therapeutics Inc, Key Competitors 36

Karyopharm Therapeutics Inc, Key Employees 37

Karyopharm Therapeutics Inc, Subsidiaries 38

List Of Figures, Charts and Diagrams
in Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]

List of Figures

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Additional Details

Publisher

Global Data

Publisher Information

Reference

226958 | GDPH259175D

Number of Pages

104

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
22 Aug 2017 by Global Data USD $250 More Info
Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
07 Aug 2017 by Global Data USD $300 More Info
Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
15 May 2017 by Global Data USD $300 More Info
Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
26 Apr 2017 by Global Data USD $250 More Info
Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
20 Mar 2017 by Global Data USD $250 More Info
Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
13 Jan 2017 by Global Data USD $300 More Info
Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical comp...
30 Nov 2016 by Global Data USD $250 More Info
Karyopharm Therapeutics, Inc. (KPTI) - Financial and Strategic SWOT Analysis Review
SummaryKaryopharm Therapeutics, Inc. (Karyopharm Therapeutics) is a clinical-stage pharmaceutical co...
11 Jul 2016 by Global Data USD $300 More Info
Karyopharm Therapeutics, Inc. (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc. (Karyopharm) is a clinical-stage pharmaceutical company that is ...
11 May 2016 by Global Data USD $250 More Info
Karyopharm Therapeutics, Inc. (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryKaryopharm Therapeutics Inc. (Karyopharm) is a clinical-stage pharmaceutical company that is ...
14 Mar 2016 by Global Data USD $250 More Info

This report is published by Global Data

Download Free Report Summary PDF

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data